Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
PTIXProtagenic Therapeutics, Inc.\new
| Figure | PTIXProtagenic Therapeutics, Inc.\newFY2026 · Mar |
|---|---|
| Revenue | $0.00 |
| Revenue, yoy | — |
| Net income | $1.37M |
| Net income, yoy | +138.1% |
| Net margin | — |
| Free cash flow | $2.81M |
| FCF margin | — |
| EPS, diluted | $0.59 |
Add another company.
Annual · FY2022–FY2026 · USD
From SEC EDGARSame fiscal periods, as filed